| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
7-ADCA targets penicillin-binding proteins (PBPs), which are essential for maintaining the structural integrity of bacterial cell walls. As a β-lactam nucleus, it inhibits bacterial cell wall synthesis. It is a key intermediate used to synthesize cephalosporin antibiotics with various side chains.
|
|---|---|
| ln Vitro |
In vitro, 7-ADCA serves as the core structure for semi-synthetic cephalosporins. It has intrinsic antibacterial activity as a β-lactam compound. Its primary role is as a chemical intermediate rather than a direct therapeutic agent. It is used in enzymatic and chemical synthesis of cephalosporin antibiotics.
|
| ln Vivo |
In vivo, 7-ADCA is not administered directly as a therapeutic agent but is used to synthesize active cephalosporin antibiotics. The resulting cephalosporins exhibit antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria. The compound is a crucial intermediate in the pharmaceutical industry.
|
| Enzyme Assay |
Cell-free assays for 7-ADCA: β-lactamase stability assays can be performed by incubating the compound with β-lactamase enzymes and monitoring the hydrolysis of the β-lactam ring by spectrophotometry. PBPs binding assays are performed using radiolabeled penicillin or fluorescent probes. Antibacterial activity is assessed by MIC assays using bacterial cultures.
|
| Cell Assay |
Cellular assays for 7-ADCA: bacterial cultures (e.g., E. coli, S. aureus) are treated with 7-ADCA or its semi-synthetic derivatives. Bacterial growth inhibition is measured by OD600 or colony counting. PBP binding is assessed by competition assays using fluorescent penicillin. Cell wall integrity is evaluated by osmotic shock or electron microscopy.
|
| Animal Protocol |
In vivo animal studies for 7-ADCA: the compound itself is not typically tested in animals as a therapeutic agent. Instead, the semi-synthetic cephalosporins derived from 7-ADCA are tested in animal models of infection. Efficacy, pharmacokinetics, and toxicity of the resulting antibiotics are evaluated in standard animal infection models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 7-ADCA: as a small molecule (molecular weight 214.24), it may have moderate bioavailability. However, it is not used as a therapeutic agent. The pharmacokinetics of cephalosporin antibiotics derived from 7-ADCA depend on the specific side chains attached. The compound is primarily used in chemical synthesis.
|
| Toxicity/Toxicokinetics |
Toxicity of 7-ADCA: as a β-lactam intermediate, it may have low toxicity. However, β-lactam compounds can cause allergic reactions in sensitized individuals. The compound is for research and industrial use and not for human consumption. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
7β-Aminodeacetoxycephalosporinic acid is a cephalosporin monocarboxylic acid derivative. Its structure is based on cephalosporinic acid, but after deacetoxylation, it acquires a 7β-amino group. It is a monocarboxylic acid and also a cephalosporin. Its function is related to that of cephalosporins.
7-ADCA is a key intermediate in the synthesis of many cephalosporin antibiotics. It is produced industrially from penicillin G using enzymatic deacylation. It is a crucial building block for the pharmaceutical industry. It is available as a research and industrial chemical. |
| Molecular Formula |
C8H10N2O3S
|
|---|---|
| Molecular Weight |
214.24
|
| Exact Mass |
214.041
|
| CAS # |
22252-43-3
|
| PubChem CID |
33498
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
517.6±50.0 °C at 760 mmHg
|
| Melting Point |
234ºC (dec.)
|
| Flash Point |
266.8±30.1 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.698
|
| LogP |
-0.81
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
353
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC1=C(N2[C@@H]([C@@H](C2=O)N)SC1)C(=O)O
|
| InChi Key |
NVIAYEIXYQCDAN-CLZZGJSISA-N
|
| InChi Code |
InChI=1S/C8H10N2O3S/c1-3-2-14-7-4(9)6(11)10(7)5(3)8(12)13/h4,7H,2,9H2,1H3,(H,12,13)/t4-,7-/m1/s1
|
| Chemical Name |
(6R,7R)-7-amino-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
25 % w/v ammonia solution: 50 mg/mL (233.38 mM)
NH4OH: 50 mg/mL (233.38 mM) H2O: 41.67 mg/mL (194.50 mM） |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6677 mL | 23.3383 mL | 46.6766 mL | |
| 5 mM | 0.9335 mL | 4.6677 mL | 9.3353 mL | |
| 10 mM | 0.4668 mL | 2.3338 mL | 4.6677 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
